Menu Search
Equities

Alzinova AB

78D:FRA

Alzinova AB

Actions
  • Price (EUR)0.2925
  • Today's Change0.005 / 1.56%
  • Shares traded1.08k
  • 1 Year change+91.28%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.

  • Revenue in SEK (TTM)300.00k
  • Net income in SEK-18.12m
  • Incorporated2011
  • Employees5.00
  • Location
    Alzinova ABAstraZeneca BioVentureHubPepparedsleden 1MOELNDAL 431 83SwedenSWE
  • Phone+46 317865163
  • Websitehttps://www.alzinova.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.